Table 1 Clinicopathological features of the overall population at diagnosis.
From: Evolution of HER2-low expression from primary to recurrent breast cancer
N (%) or median (Q1–Q3) | |
|---|---|
Total | 547 (100) |
Age at primary BC diagnosis (yy), median (Q1–Q3) | 51.6 (43.4–62.6) |
Primary BC histotype | |
Ductal | 437 (79.9) |
Non-ductal | 104 (19.0) |
Missing | 6 (1.1) |
Primary BC histologic grade | |
1 | 27 (5.0) |
2 | 187 (34.2) |
3 | 308 (56.3) |
Missing | 25 (4.5) |
Stage at BC diagnosis | |
Early | 509 (93.1) |
Stage IV | 32 (5.9) |
Missing | 6 (1.1) |
Primary BC phenotype | |
HR + /HER2− | 336 (61.4) |
Triple-negative | 79 (14.5) |
HER2 + | 132 (24.1) |
Missing | 0 (0.0) |
Treatment for early BC | |
Adjuvant | |
Chemotherapy | 282 (51.5) |
Hormonal therapy | 350 (64.0) |
Anti-HER2 | 68 (12.4) |
Neoadjuvant | |
Chemotheapy | 151 (27.6) |
Hormonal therapy | 14 (2.5) |
Anti-HER2 | 37 (6.8) |
Treatment for relapsed/stage IV BC | |
Chemotherapy | 430 (78.6) |
Hormonal therapy | 364 (66.5) |
Anti-HER2 | 40 (7.3) |
131 (23.9) | |
Time from primary BC diagnosis and BC relapse (mo), median (Q1-Q3) | 39.4 (20.3–81.5) |
Time from recurrent BC diagnosis and biopsy of relapse (mo), median (Q1-Q3) | 0.2 (0.0–6.9) |
